Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.26
CPHI's Cash to Debt is ranked lower than
83% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. CPHI: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
CPHI' s 10-Year Cash to Debt Range
Min: 0  Med: 0.94 Max: No Debt
Current: 0.26
Equity to Asset 0.78
CPHI's Equity to Asset is ranked higher than
75% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. CPHI: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CPHI' s 10-Year Equity to Asset Range
Min: -10  Med: 0.86 Max: 0.97
Current: 0.78
-10
0.97
F-Score: 3
Z-Score: 0.62
M-Score: -3.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -112.15
CPHI's Operating margin (%) is ranked lower than
90% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.92 vs. CPHI: -112.15 )
Ranked among companies with meaningful Operating margin (%) only.
CPHI' s 10-Year Operating margin (%) Range
Min: -1932.43  Med: 18.99 Max: 39.48
Current: -112.15
-1932.43
39.48
Net-margin (%) -117.53
CPHI's Net-margin (%) is ranked lower than
90% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. CPHI: -117.53 )
Ranked among companies with meaningful Net-margin (%) only.
CPHI' s 10-Year Net-margin (%) Range
Min: -2983.78  Med: 16.11 Max: 39.31
Current: -117.53
-2983.78
39.31
ROE (%) -25.30
CPHI's ROE (%) is ranked lower than
82% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.43 vs. CPHI: -25.30 )
Ranked among companies with meaningful ROE (%) only.
CPHI' s 10-Year ROE (%) Range
Min: -21.78  Med: 22.48 Max: 82.39
Current: -25.3
-21.78
82.39
ROA (%) -20.38
CPHI's ROA (%) is ranked lower than
84% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. CPHI: -20.38 )
Ranked among companies with meaningful ROA (%) only.
CPHI' s 10-Year ROA (%) Range
Min: -337.12  Med: 13.38 Max: 60.23
Current: -20.38
-337.12
60.23
ROC (Joel Greenblatt) (%) -33.55
CPHI's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.24 vs. CPHI: -33.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPHI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -305.76  Med: 24.35 Max: 65.47
Current: -33.55
-305.76
65.47
Revenue Growth (3Y)(%) -32.70
CPHI's Revenue Growth (3Y)(%) is ranked lower than
95% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. CPHI: -32.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CPHI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 4.40 Max: 181.3
Current: -32.7
0
181.3
» CPHI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CPHI Guru Trades in Q3 2014

Jim Simons 154,500 sh (+5.32%)
» More
Q4 2014

CPHI Guru Trades in Q4 2014

Jim Simons 136,300 sh (-11.78%)
» More
Q1 2015

CPHI Guru Trades in Q1 2015

Jim Simons 132,000 sh (-3.15%)
» More
Q2 2015

CPHI Guru Trades in Q2 2015

Jim Simons 122,500 sh (-7.20%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.11
CPHI's P/B is ranked higher than
99% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. CPHI: 0.11 )
Ranked among companies with meaningful P/B only.
CPHI' s 10-Year P/B Range
Min: 0.06  Med: 0.86 Max: 8.03
Current: 0.11
0.06
8.03
P/S 0.47
CPHI's P/S is ranked higher than
92% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. CPHI: 0.47 )
Ranked among companies with meaningful P/S only.
CPHI' s 10-Year P/S Range
Min: 0.16  Med: 1.40 Max: 66.67
Current: 0.47
0.16
66.67
PFCF 25.00
CPHI's PFCF is ranked higher than
69% of the 274 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.71 vs. CPHI: 25.00 )
Ranked among companies with meaningful PFCF only.
CPHI' s 10-Year PFCF Range
Min: 1.46  Med: 17.99 Max: 99999999.99
Current: 25
1.46
99999999.99
POCF 6.25
CPHI's POCF is ranked higher than
94% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.63 vs. CPHI: 6.25 )
Ranked among companies with meaningful POCF only.
CPHI' s 10-Year POCF Range
Min: 1.26  Med: 7.38 Max: 55.17
Current: 6.25
1.26
55.17
Shiller P/E 15.72
CPHI's Shiller P/E is ranked higher than
82% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. CPHI: 15.72 )
Ranked among companies with meaningful Shiller P/E only.
CPHI' s 10-Year Shiller P/E Range
Min: 0.49  Med: 2.01 Max: 198.85
Current: 15.72
0.49
198.85
Current Ratio 3.07
CPHI's Current Ratio is ranked higher than
63% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. CPHI: 3.07 )
Ranked among companies with meaningful Current Ratio only.
CPHI' s 10-Year Current Ratio Range
Min: 0.01  Med: 6.78 Max: 23.65
Current: 3.07
0.01
23.65
Quick Ratio 2.13
CPHI's Quick Ratio is ranked higher than
60% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. CPHI: 2.13 )
Ranked among companies with meaningful Quick Ratio only.
CPHI' s 10-Year Quick Ratio Range
Min: 0.01  Med: 4.79 Max: 17.34
Current: 2.13
0.01
17.34
Days Inventory 283.84
CPHI's Days Inventory is ranked lower than
94% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 111.99 vs. CPHI: 283.84 )
Ranked among companies with meaningful Days Inventory only.
CPHI' s 10-Year Days Inventory Range
Min: 138.59  Med: 196.08 Max: 375
Current: 283.84
138.59
375
Days Sales Outstanding 271.84
CPHI's Days Sales Outstanding is ranked lower than
98% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.80 vs. CPHI: 271.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPHI' s 10-Year Days Sales Outstanding Range
Min: 6.64  Med: 303.12 Max: 502.3
Current: 271.84
6.64
502.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 0.60
CPHI's Price/Net Current Asset Value is ranked higher than
98% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. CPHI: 0.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPHI' s 10-Year Price/Net Current Asset Value Range
Min: 0.09  Med: 1.11 Max: 16.67
Current: 0.6
0.09
16.67
Price/Tangible Book 0.12
CPHI's Price/Tangible Book is ranked higher than
99% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. CPHI: 0.12 )
Ranked among companies with meaningful Price/Tangible Book only.
CPHI' s 10-Year Price/Tangible Book Range
Min: 0.06  Med: 0.98 Max: 6.06
Current: 0.12
0.06
6.06
Price/Projected FCF 0.19
CPHI's Price/Projected FCF is ranked higher than
98% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.70 vs. CPHI: 0.19 )
Ranked among companies with meaningful Price/Projected FCF only.
CPHI' s 10-Year Price/Projected FCF Range
Min: 0.08  Med: 1.04 Max: 4.12
Current: 0.19
0.08
4.12
Price/Median PS Value 0.34
CPHI's Price/Median PS Value is ranked higher than
95% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. CPHI: 0.34 )
Ranked among companies with meaningful Price/Median PS Value only.
CPHI' s 10-Year Price/Median PS Value Range
Min: 0.11  Med: 1.30 Max: 45
Current: 0.34
0.11
45
Earnings Yield (Greenblatt) (%) -105.30
CPHI's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. CPHI: -105.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPHI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.2  Med: 20.20 Max: 139
Current: -105.3
1.2
139
Forward Rate of Return (Yacktman) (%) -32.81
CPHI's Forward Rate of Return (Yacktman) (%) is ranked lower than
94% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.88 vs. CPHI: -32.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CPHI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -36  Med: -2.10 Max: 41.5
Current: -32.81
-36
41.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:XQJ.Germany,
China Pharma Holding, Inc., a Delaware corporation was incorporated on January 28, 1999 under the name 'Softstone, Inc.' On March 16, 2006; it changed its corporate name to China Pharma Holdings, Inc. The company develops, manufactures and markets pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions in the People's Republic of China (the 'PRC'). All of its operations are conducted in the PRC, where its manufacturing facilities are located. It manufactures pharmaceutical products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions and granules. All of its pharmaceutical products are sold on a prescription basis and have been approved for at least one or more therapeutic indications by the Chinese State Food and Drug Administration (the 'SFDA') based upon demonstrated safety and efficacy. At December 31, 2012, it manufactured 20 pharmaceutical products for a variety of diseases and medical indications. It markets and sells its products through 16 sales offices covering all major cities and provinces in the PRC. Its product portfolio includes both branded and generic drugs that it either developed or was developed by it in joint research efforts with its academic institutional partners or, to a lesser extent, acquired from third parties. It develops new products in-house as well as through relationships with several research institutes, including the Chinese Academy of Sciences, China University of Pharmaceuticals, Sichuan University, Chongqing Medical Industry Institute and the Military Medical Academy Basic Medical Science Institute. The Company sells its prescription drugs to hospitals and clinics through its distribution system which is comprised of 1,220 independent regional distributors. In November 2008, it purchased the patented medical formula for a cerebral/cardio-vascular indication and the manufacturing processes for that product candidate from a third party laboratory. In connection with that acquisition, it obtained the title of the patent. This patent expires in 2025. At December 31, 2012, it owned 17 registered trademarks, including marks for nine of the 20 pharmaceutical products it manufacture, including the tradenames Funalin, Fukexing, Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang and Shenkaineng, as well as marks for its AFGF logo, its HPS logo, its two HELPSON logos and four other logos.
» More Articles for CPHI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CHINA PHARMA HOLDINGS, INC. Financials Aug 21 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2015
China Pharma Holdings, Inc. Reports Second Quarter 2015 Financial Results Aug 14 2015
CPHI to Hold Second Quarter 2015 Earnings Conference Call on Friday August 14, 2015 at 8:30 a.m. EDT Aug 07 2015
CPHI Received CNY 9.6 Million In Government Subsidies Jul 31 2015
China Pharma Holdings, Inc. Reports First Quarter 2015 Financial Results May 12 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
CPHI to Hold First Quarter 2015 Earnings Conference Call on Tuesday, May 12, 2015 at 8:30 a.m. ET May 07 2015
China Pharma Holdings, Inc. Reports Full Year 2014 Financial Results Mar 31 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-K, Annual Report Mar 30 2015
CPHI to Hold Fiscal Year 2014 Earnings Conference Call on Tuesday, March 31, 2015 at 8:30 a.m. ET Mar 17 2015
CHINA PHARMA HOLDINGS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 31 2014
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
China Pharma Holdings, Inc. Reports Third Quarter 2014 Financial Results Nov 14 2014
CPHI to Hold third Quarter 2014 Earnings Conference Call on Friday November 14, 2014 at 8:30 a.m. ET Nov 05 2014
3 Stocks Pushing The Drugs Industry Lower Oct 15 2014
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK